GlaxoSmithKline Pharmaceuticals Limited · NSE:GLAXO
GlaxoSmithKline Pharmaceuticals — FY2011 Earnings Presentation
11 slides from GlaxoSmithKline Pharmaceuticals's earnings presentation, Feb 29, 2012
Slide 1: Results 2011
e csk An Kline Results 2011 29% Feb 2012
Slide 2: A Multi-Faceted Indian Business Focussed on Our Strategic Drivers of Growth
A Multi- Faceted Indian Business Focussed on Our Strategic Drivers of Growth Scale up our Base Drive our Innovative Build the Vaccines business Brands business Introducing new products Re-energising our Base Growing our base vaccine from the GSK pipeline business business Reinvigorating brands Expan
Slide 3: Net Sales
Net Sales INR Mn Q4 2011 2011 INR Mn Gr % INR Mn Gr % Net Sales 5,660 15.4 23,380 10.7 Pharma 5,396 18.2 22,049 12.5 Iodex 238 30.9 966 9.5 Exports 26 (40.7) 365 (42.2)
Slide 4: Performance Across Business Verticals 2011 vs 2010
Performance Across Business Verticals 2011 vs 2010 Vaccines 58% Specialties +16% Mass Specialty +11% Mass Markets 4%
Slide 5: Creating a broader portfolio of potential high value assets
Creating a broader portfolio of potential high value assets New products contributions to growth in 2011 27% New Products contributions to Total Rx Sales 9% 2009 2010 2011
Slide 6: Executive Summary: Financials
Executive Summary: Financials INR Mn Q4 2011 2011 INR Mn Gr % INR Mn Gr % Net Sales 5,660 15.4 23,380 10.7 Pharma 5,396 18.2 22,049 12.5 Iodex 238 30.9 966 9.5 Exports 26 (40.7) 365 (42.2) Gross Margin 3,338 8.5 14,296 7.1 % to Sales 59% 61% Staff Costs 703 (8.3) 2,784 (15.6) % to Sales 12% 12% Othe
Slide 7: Exceptional Items
Exceptional Items INR Mn 2011 Expenses on rationalisation initiatives mainly relating to a manufacturing site - Voluntary retirement scheme (91) - Others (143) Provisions for Government's demand in respect of Betamethasone bulk drugs and formulations (3,005) Actuarial gain/(loss) on employee benefit
Slide 8: Cash Flow
Cash Flow INR Mn 2011 INR Mn Profit before taxation and exceptional items 9,216 Depreciation and other non-operating activities (1,537) Increase/(Decrease) in Working Capital (743) Cash generated from operations 6,936 Taxation (3,093) Cash flow before exceptional items 3,843 Exceptional items (630)
Slide 9: Financial performance
Financial performance EPS and Book Value per share (INR) Return on Avg. Net Worth and Avg. Capital Employed (%) 68.6 74.5 42 ` RONW 59.6 52.9 ROCE 46.8 41 ` 40 40 40 33 279 228 32 208 31 31 182 31 161 B ook value EPS 2007 2008 2009 2010 2011 2007 2008 2009 2010 2011 70% Dividend Payout (INR) 18 68%
Slide 10: Corporate Rankings
Corporate Rankings Net Profit Market EPS Tax Paid Total Total Cap Assets Income 89 58 94 57 207 249
Slide 11: csk An Kline
e csk An Kline
GlaxoSmithKline Pharmaceuticals — FY2011 Earnings Presentation on 6ix